Prosecution Insights
Last updated: November 20, 2026
Application No. 19/430,719

ACTIVATION OF LATE RESPONSE GENES USING NEUROMODULATION

Non-Final OA §103§DOUBLEPATENT
Filed
Dec 23, 2025
Priority
Oct 13, 2021 — provisional 63/255,339 +2 more
Examiner
NGUYEN, HIEN NGOC
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
GE Precision Healthcare LLC
OA Round
1 (Non-Final)
53%
Grant Probability
Moderate
1-2
OA Rounds
3y 0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
419 granted / 795 resolved
-17.3% vs TC avg
Strong +41% interview lift
Without
With
+41.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
32 currently pending
Career history
852
Total Applications
across all art units

Statute-Specific Performance

§101
7.3%
-32.7% vs TC avg
§103
51.6%
+11.6% vs TC avg
§102
10.1%
-29.9% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 795 resolved cases

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 7-8, 20, 30-31, 34-35, 39 and 41-42 of copending Application No. 18/700,499 in view of Puleo et al. (US 2020/0069975). Even though the claims on both applications are not the same they both claim the same system of treating metabolic disorder using ultrasound stimulation to activate late-response gene. The current application claim a specific metabolic disorder of treating weight loss (prevent weight gain). This is a provisional nonstatutory double patenting rejection. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over Puleo et al. (US 2020/0054228 (provided in the IDS)), in view of Azamian et al. (US 2013/0178910 (provided in the IDS)) and further in view of Puleo et al. (US 2020/0069975). Addressing claim 1, Puleo discloses A system for treating a metabolic disorder in a subject, the system comprising: an energy application device comprising at least one ultrasound transducer configured to non-invasively target a tissue of the subject (see Fig. 3, [0007], [0086], [0091] and [0096]); a pulse generator configured to be connected to the at least one ultrasound transducer to stimulate the tissue using the at least one ultrasound transducer for a duration that is effective to alleviate the metabolic disorder (see Figs. 1-3, [0100-0101], [0119] and [0184]; change gene to treat diabetes; the claim is broadly claim ultrasound transducer stimulation for a duration that is effective to thereby treat or alleviate the metabolic disorder; Puleo discloses ultrasound stimulation of several minutes, 30 minutes to several hours; this is within the time frame disclose by applicant’s specification to effectively treat diabetes); a controller configured to: non-invasively apply multi-site neuromodulation to modulate more than one peripheral nerve pathway, wherein the more than one peripheral nerve pathway are in communication with each other or with an integrating neuron or a cell in a central nervous system, wherein the noninvasive multi-site neuromodulation comprises ultrasound stimulation of a hepatoportal plexus region and of a superior mesenteric plexus region, and wherein the metabolic disorder is alleviated by weight reduction (see Figs. 1-3, [0004], [0007], [0086], [0091], [0096], [0104], [0177], [0186] and [0188]; stimulate multiple sites and the nerve are in communication with each other or with an integrating neuron or a cell in a central nervous system). Puleo does not disclose ultrasound stimulation of a hepatoportal plexus region and of a superior mesenteric plexus region and alleviated by weight reduction. Azamian discloses the hepatoportal plexus and the superior mesenteric plexus (see [0080], stimulate mesenteric plexus in addition to nerve fibers in the hepatic plexus/hepatoportal plexus). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Puleo to stimulate superior plexus in addition to hepatic plexus because this helps metabolic conditions (see [0080]). Using ultrasound modulation treat weight reduction/loss is well-known in the ultrasound therapy field. In the same field of endeavor, Puleo (US 2020/0069975) explicitly alleviated by weight reduction (see [0032]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Puleo (US 2020/0054228) to alleviated by weight reduction as taught by Puleo (US 2020/0069975) because this allows physician to use neuromodulation system to promote weight loss (see [0032]). 4. Addressing claims 2-3 and 6-10, Puleo (US 2020/0054228) discloses: addressing claim 2, wherein the controller is configured to: receive feedback indicative of a change in concentration of one or more molecules relative to a baseline concentration of the one or more molecules in response to the multi- site neuromodulation; and adjust one or more modulation parameters of the energy application device based on the feedback (see [0109], [0114], claim 63 and [0122]). addressing claim 3, wherein the one or more modulation parameters comprise pulse amplitude, pulse width, pulse frequency, or a combination thereof (see [0109]). addressing claim 6. wherein the multi-site neuromodulation activates late- response genes in the subject (see Figs. 1-3, [0096], [0100-0101], [0104], [0119] and [0184]; Puleo discloses ultrasound stimulation of several minutes, 30 minutes to several hours; this is within the time frame disclose by applicant’s specification to effectively activate late-response genes (see applicant’s specification paragraphs [0058] and [0064]); activate late-response genes is a result of stimulation for a duration of time). addressing claim 7, wherein the late-response gene comprises a fibroblast growth factor 1 (FGF1) gene (see Fig. 3, [0007], [0086], [0091], [0096] and [0100-0101]; examiner interprets the claim as stimulate gene/cell that has and responsible for producing FGF1; as see in applicant’s specification paragraphs [0052] and [0059], energy is directed to a target tissue (e.g., the hepatoportal plexus and/or superior mesenteric plexus) for a duration effective to activate late response genes (e.g., the FGF1 gene); FGF1 production is a result of apply energy to the target for a duration; Puleo discloses apply energy to the target for the same range duration as applicant therefore result in FGF1 production). addressing claim 8, wherein the late-response gene modulates a protein kinase R (PKR)-like endoplasmic reticulum kinase (pERK) pathway (see Fig. 3, [0007], [0086], [0091], [0096] and [0100-0101]; modulates a protein kinase R (PKR)-like endoplasmic reticulum kinase (pERK) pathway is a result of activate late-response gene and activate late-response gene result from apply energy to the target for a duration of time; Puleo discloses apply energy to the target for a duration of time as applicant claim therefore result in activating late response gene which in turn modulates a protein kinase R (PKR)-like endoplasmic reticulum kinase (pERK) pathway). addressing claim 9, wherein the integrating neuron is an interneuron (see [0004], [0007], [0086], [0091], [0177], [0186], [0188]; the stimulation tissue contain nerve that communicate to the brain, spinal cord, central nervous system that contain interneuron). addressing claim 10, wherein the integrating neuron or the cell connects neuropeptide Y (NPY) neurons and proopiomelanocortin (POMC) neurons (see [0058-0059] and [0184]; nerve pathways are in communication with NPY and POMC). Addressing claims 4-5, Azamian discloses: addressing claim 4, wherein the controller is configured to: apply a first set of ultrasound energy pulses to the hepatoportal plexus region; and apply a second set of ultrasound energy pulses to the superior mesenteric plexus region (see [0080] and see Puleo (US 2020/0054228) paragraph [0104]; Puleo explicitly discloses modulation different sites with first and second set of ultrasound energy; Azamian explicitly discloses the sites are hepatoportal plexus region and superior mesenteric plexus region). addressing claim 5, wherein the second set of ultrasound energy pulses are applied at a different time relative to the first set of ultrasound energy pulses (see [0080] and see Puleo (US 2020/0054228) paragraph [0104]; different sites with different modulation parameters is applied at different time because only one ultrasound treatment probe). Addressing claims 11-12, 16 and 18-20, the system claims 1-2, 6 and 9 perform the method and include a tangible, non-transitory, machine-readable medium therefore claims 11-12, 16 and 18-20 are being rejected for the same reason as claims 1-2, 6 and 9. Addressing claims 13-14 and 17, Puleo (US 2020/0054228) discloses: addressing claim 13, wherein activating the late-response genes comprises activating sustained expression of immediate early genes (see Fig. 3, [0007], [0086], [0091], [0096] and [0100-0101]; Puleo apply energy to the target region for a duration of time which result in sustained expression of immediate early genes). addressing claim 14, wherein the late-response genes are in the hypothalamus of the subject (see Fig. 3, [0007], [0086], [0091], [0096], [0100-0101] and [0184]; Puleo disclose stimulate a duration that is effective to produce FGF1; FGF1 is produced in the hypothalamus; the stimulation effect genes and nerves in the hypothalamus). addressing claim 17, wherein the ultrasound stimulation is non-ablative (see [0133]; “at no point, will energies reach levels associated with thermal damage & ablation/cavitation”) Addressing claims 15, Puleo (US 2020/0069975) discloses: addressing claim 15, wherein the metabolic disorder is associated with weight gain (see [0032]; ultrasound modulation to promote weight loss is associated with weight gain or prevent weight gain). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to HIEN NGOC NGUYEN whose telephone number is (571)270-7031. The examiner can normally be reached Monday-Thursday 8:30am-6:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Kozak can be reached at 571-270-0552. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HIEN N NGUYEN/ Primary Examiner Art Unit 3797
Read full office action

Prosecution Timeline

Dec 23, 2025
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12789016
HISTOTRIPSY EXCITATION SEQUENCES OPTIMIZED FOR BUBBLE CLOUD FORMATION USING SHOCK SCATTERING
7y 6m to grant Granted Nov 10, 2026
Patent 12773227
SURGICAL SYSTEM AND METHODS
1y 11m to grant Granted Oct 27, 2026
Patent 12765950
ELECTROMAGNETIC DISTORTION DETECTION
4y 2m to grant Granted Oct 20, 2026
Patent 12746413
HISTOTRIPSY EXCITATION SEQUENCES OPTIMIZED FOR BUBBLE CLOUD FORMATION USING SHOCK SCATTERING
2y 3m to grant Granted Sep 29, 2026
Patent 12749188
BONE STRENGTH SIMULATION CALCULATION METHOD AND DEVICE, AND STORAGE MEDIUM
1y 8m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
53%
Grant Probability
94%
With Interview (+41.2%)
3y 11m (~3y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month